8,326 Shares in Zai Lab Limited (NASDAQ:ZLAB) Purchased by RWC Asset Management LLP

RWC Asset Management LLP acquired a new position in shares of Zai Lab Limited (NASDAQ:ZLAB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 8,326 shares of the company’s stock, valued at approximately $228,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hsbc Holdings PLC increased its position in shares of Zai Lab by 251.1% during the third quarter. Hsbc Holdings PLC now owns 327,781 shares of the company’s stock valued at $7,968,000 after acquiring an additional 234,431 shares during the last quarter. UBS Group AG increased its position in shares of Zai Lab by 312.4% during the third quarter. UBS Group AG now owns 288,981 shares of the company’s stock valued at $7,025,000 after acquiring an additional 218,907 shares during the last quarter. XY Capital Ltd acquired a new stake in shares of Zai Lab during the third quarter valued at about $3,397,000. TD Asset Management Inc increased its position in shares of Zai Lab by 114.6% during the third quarter. TD Asset Management Inc now owns 216,970 shares of the company’s stock valued at $5,275,000 after acquiring an additional 115,885 shares during the last quarter. Finally, Bamco Inc. NY increased its position in shares of Zai Lab by 4.5% during the third quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock valued at $38,394,000 after acquiring an additional 67,288 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZLAB has been the subject of a number of recent analyst reports. Citigroup dropped their price target on shares of Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Friday, January 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.22.

Zai Lab Price Performance

Shares of NASDAQ ZLAB traded up $0.17 during midday trading on Friday, hitting $15.91. The company’s stock had a trading volume of 364,581 shares, compared to its average volume of 470,952. The business’s fifty day simple moving average is $17.45 and its two-hundred day simple moving average is $22.58. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $39.50. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -4.61 and a beta of 1.10.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The business had revenue of $65.83 million during the quarter, compared to analysts’ expectations of $70.41 million. Analysts anticipate that Zai Lab Limited will post -3.27 EPS for the current fiscal year.

Insider Activity

In related news, insider Rafael Amado sold 2,544 shares of Zai Lab stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $18.86, for a total value of $47,979.84. Following the completion of the transaction, the insider now owns 20,093 shares in the company, valued at $378,953.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Ying Du sold 5,787 shares of Zai Lab stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $16.15, for a total value of $93,460.05. Following the completion of the transaction, the chief executive officer now owns 1,107,972 shares in the company, valued at $17,893,747.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rafael Amado sold 2,544 shares of Zai Lab stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $18.86, for a total transaction of $47,979.84. Following the completion of the transaction, the insider now owns 20,093 shares of the company’s stock, valued at approximately $378,953.98. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,568 shares of company stock valued at $208,508. 5.23% of the stock is currently owned by company insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.